A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides update...
Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, signals strong investor confidenc...
US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date ...
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabete...
Wellumio, a New Zealand-based medical technology company developing a portable neuroimaging device for rapid, point-of-care stroke detection, has raised $7...
MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada Formerra, a leader in performance materials distribution, to...
AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...
Transaction expands MedImpact’s scale, expertise, and health solutions portfolio while maintaining Sav-Rx’s mission and service model ...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
Baoting Establishes World's First County-Level "Living Laboratory," Developing 1.5°C Proactive Health Standards Breaking with decades of capit...
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than ...
- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...
© 2026 Biopharma Boardroom. All Rights Reserved.
